Want to see NDRA full AI Analyst Report?
NDRA Stock Chart & Stats
$4.86
-$0.08(-1.65%)
At close: 4:00 PM EDT
$4.86
-$0.08(-1.65%)
Day’s Range― - ―
52-Week Range$2.96 - $9.85
Previous Close$4.78
Volume5.95K
Average Volume (3M)514.97K
Market Cap
$6.73M
Enterprise Value$1.95
Total Cash (Recent Filing)$1.74M
Total Debt (Recent Filing)$429.27K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 16, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.33
Shares Outstanding1,499,838
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside414.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest and refinancing pressure, preserving flexibility while ENDRA develops its platform or pursues strategic alternatives. This is a meaningful balance-sheet advantage, although it does not offset the company’s reliance on external funding.
Narrowing LossesThe sustained reduction in net losses indicates some progress in cost control and may extend the company’s operating runway. However, the improvement remains preliminary because it has not yet been accompanied by meaningful revenue or positive cash flow.
Strategic Funding PivotIf completed, the transaction could provide substantially more capital and replace ENDRA’s stalled legacy model with exposure to a larger development platform. The funding and asset contribution may improve strategic relevance, but approvals and execution remain necessary.
Bears Say
No Commercial RevenuePersistent zero revenue shows that ENDRA has not demonstrated commercial adoption of its imaging technology. Without customers or recurring sales, the business lacks an internally funded growth engine and remains dependent on financing, partnerships, or a successful strategic transaction.
Persistent Cash BurnMaterial operating and free-cash-flow deficits reduce financial durability and require continued access to capital. Renewed cash-flow pressure can dilute existing holders, constrain investment in product development, and weaken negotiating leverage in future financing or strategic transactions.
Listing And Control RiskThe monitoring period leaves the company exposed to renewed listing deficiencies and potential delisting consequences. Separately, the proposed dual-class structure and ASPI control could limit existing shareholders’ influence and increase governance risk after the strategic transition.
ENDRA Life Sciences News
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $2.96 and its highest was $9.85 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $6.73M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Nov 16, 2026 which is in 83 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on Aug 17, 2026. The company reported -$0.84 earnings per share for the quarter, the consensus estimate of -$0.84 by $0.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -0.84.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 1,499,838 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$0.84 in its last earnings report, expectations of -$0.84. Following the earnings report the stock price went up 0.447%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
NDRA Stock 12 Month Forecast
Average Price Target
$25.00
▲(414.40% Upside)
Technical Analysis
Ownership Overview
26.90% Insiders
0.70% Mutual Funds
5.85% Other Institutional Investors
66.07% Public Companies and
Individual Investors